Document Detail


Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder.
MedLine Citation:
PMID:  15602116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There has been growing interest in the concept of resilience and the question as to whether psychotropic medications or psychosocial treatments might have resilience-enhancing effects. This pilot study investigates resilience in a sample of patients with post-traumatic stress disorder (PTSD) before and after treatment. Effects of treatment with tiagabine, fluoxetine, sertraline alone, and sertraline with cognitive behavioural therapy on resilience were assessed using the Connor-Davidson Resilience Scale (CD-RISC). Changes in resilience after treatment were measured and response to treatment was predicted from demographic, resilience and baseline disability measures. Changes in resilience following treatment were statistically significant. Items that showed the greatest change related to confidence, control, coping, knowing where to turn for help and adaptability. Items showing the least change related to religious and existential aspects of resiliency, effort, acting on a hunch, decision-making and goals. In linear and logistic regression models, gender, baseline CD-RISC score, baseline Sheehan Disability Scale score and an individual item from the CD-RISC scale, 'Sense of Humor', were significant predictors of response to treatment. Treatment of PTSD significantly improved resilience and reduced symptoms in this sample. Further controlled studies are indicated.
Authors:
Jonathan R T Davidson; Victoria M Payne; Kathryn M Connor; Edna B Foa; Barbara O Rothbaum; Michael A Hertzberg; Richard H Weisler
Related Documents :
11301926 - Variability and severity of depression and anxiety in post traumatic stress disorder an...
8028166 - Factors related to long-term traumatic stress responses in survivors of torture in turkey.
12417486 - Exposures to the kuwait oil fires and their association with asthma and bronchitis amon...
15149896 - One- and two-year prospective follow-up of cognitive behavior therapy or supportive psy...
11467756 - Apheresis technologies and clinical applications: the 2000 international apheresis regi...
19583756 - One- vs. five-session treatment of intra-oral injection phobia: a randomized clinical s...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International clinical psychopharmacology     Volume:  20     ISSN:  0268-1315     ISO Abbreviation:  Int Clin Psychopharmacol     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2004-12-16     Completed Date:  2005-05-10     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8609061     Medline TA:  Int Clin Psychopharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  43-8     Citation Subset:  IM    
Affiliation:
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina 27710, USA. jonathan.davidson@duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptation, Psychological*
Adult
Cognitive Therapy*
Female
Fluoxetine / therapeutic use*
GABA Agonists / therapeutic use*
Humans
Male
Middle Aged
Nipecotic Acids / therapeutic use*
Prognosis
Serotonin Uptake Inhibitors / therapeutic use*
Sertraline / therapeutic use*
Severity of Illness Index
Stress Disorders, Post-Traumatic / drug therapy,  psychology*,  therapy*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01MH56656/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/GABA Agonists; 0/Nipecotic Acids; 0/Serotonin Uptake Inhibitors; 115103-54-3/tiagabine; 54910-89-3/Fluoxetine; 79617-96-2/Sertraline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Affective psychosis following Accutane (isotretinoin) treatment.
Next Document:  Imputing response rates from means and standard deviations in meta-analyses.